

Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials

Eva M Gamper^{1*}, Jammbe Z Musoro^{2*}, Corneel Coens², Jean-Jacques Stelmes³, Claudette Falato², Mogens Groenvold⁴, Galina Velikova⁵, Kim Cocks⁶, Hans-Henning Flechtner⁸, Madeleine T King⁹, Andrew Bottomley² on behalf of the EORTC Genito-Urinary Tract Cancer Group and Quality of Life Groups

¹Innsbruck Institute of Patient-centered Outcome Research (IIPCOR), Innsbruck, Austria,
eva.gamper@iipcor.org, ORCID ID: 0000-0002-1700-4054

²European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium

³Department of Radiation Oncology, University Hospital Zurich

⁴Department of Public Health, University of Copenhagen, and Bispebjerg Hospital, Copenhagen, Denmark

⁵Leeds Institute of Cancer and Pathology, University of Leeds, St James's Hospital, Leeds, UK.

⁶Adelphi Values, Bollington, Cheshire, UK

⁸Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Magdeburg, Magdeburg, Germany

⁹University of Sydney, Faculty of Science, School of Psychology, Sydney, NSW, Australia

*Joint first authors

Corresponding Author:

Eva M Gamper

Innsbruck Institute of Patient-centered Outcome Research (IIPCOR)

6020 Innsbruck

Austria

eva.gamper@iipcor.org




Figure A.1: An overview of patient inclusion.

Abbreviations: CTCAE; common terminology criteria for adverse events, HRQOL; health-related quality of life